Solid Omental Tumors Workup
- Author: Kendrix J Evans, MD, MS; Chief Editor: John Geibel, MD, DSc, MSc, MA more...
Standard preoperative laboratory studies include the following:
Complete blood count (CBC)
Most patients undergo abdominal ultrasonography as a first-line screening imaging study. This modality can indicate the presence of a mass in the midabdomen and can differentiate cystic tumors from solid tumors; however, it usually cannot identify the primary site of the tumor and its characteristics. Consequently, computed tomography (CT) of the abdomen is the study of choice in helping to diagnose omental tumors.
CT provides anatomic details and usually identify the primary tumor site. It may also demonstrate displacement or compression on adjacent organs. In a review of primary omental leiomyosarcomas, all three cases revealed CT findings of a flat, pancakelike mass with multiple cystic spaces with enhancement of the solid areas of the masses. The masses were located in the anterior compartment of the abdomen, usually anterior to the small bowel loops and transverse colon. This differs from the appearance of omental metastatic disease on CT, which has been described as an "omental cake" owing to the thickened tumor-implanted omentum floating in ascites.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is another available modality that can aid in differentiating cystic tumors from solid tumors. MRI is not operator dependent and requires no preparation contrast medium; however, it is more time-consuming and expensive than other imaging modalities.
Positron emission tomography
When a gastrointestinal (GI) stromal tumor (GIST) is suspected, imaging with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (FDG-PET) can complement contrast CT in helping to differentiate benign tissue from malignant tissue and necrotic scar from active tumor. Baseline PET is recommended before initiation of treatment with imatinib because 80% of patients will exhibit response based on PET images.
Angiography can be helpful in patients with a suspected omental tumor. The major arterial blood supply of the greater omentum is largely from the right and left gastroepiploic arteries, which are derived from the gastroduodenal and splenic arteries. Knowledge of these vascular structures helps in diagnosing an omental tumor. Malignant tumors are favored when angiography demonstrates a hypervascular mass with neovascularity. Angiography should be performed to determine the feeding artery of the tumor as well as its vascularity.
Preoperative fine-needle aspiration (FNA) and core-needle biopsies are controversial. Although some surgeons find these procedures to be helpful in confirming the diagnosis of these abdominal masses, others argue that the risk of potentially contaminating the abdominal cavity with tumor cells is increased.
Primary omental tumors with the following histologic types have been reported:
Spindle cell sarcoma
Liposarcoma [26, 27]
Liposarcomas are further classified into the following four different subtypes[26, 27] :
The difference between benign and malignant omental tumors depends on the evaluation of many parameters (eg, size, pleomorphism, mitotic activity, necrosis, metastasis). Benign and malignant lesions are almost equally distributed.
Omental GISTs have positive staining for CD 117 (c-kit proto-oncogene protein product), which are present in the interstitial cells of Cajal (ICCs). ICCs are the pacemaker cells that are important for GI tract motility. Omental GISTs also are positive for vimentin during immunohistochemical staining. Vimentin is a protein found in cells of mesenchymal origin.
Ishida H, Ishida J. Primary tumours of the greater omentum. Eur Radiol. 1998. 8(9):1598-601. [Medline].
Imachi M, Tsukamoto N, Tsukimori K, Funakoshi K, Nakano H, Shigematsu T, et al. Malignant hemangiopericytoma of the omentum presenting as an ovarian tumor. Gynecol Oncol. 1990 Nov. 39(2):208-13. [Medline].
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2005 Jun. 19(3):547-64, vii. [Medline].
Kimura H, Maeda K, Konishi K, Tsuneda A, Tazawa K, Earashi M, et al. Primary leiomyosarcoma arising in the lesser sac: report of a case. Surg Today. 1997. 27(7):672-5. [Medline].
Niwa K, Hashimoto M, Hirano S, Mori H, Tamaya T. Primary leiomyosarcoma arising from the greater omentum in a 15-year-old girl. Gynecol Oncol. 1999 Aug. 74(2):308-10. [Medline].
Ishida J, Ishida H, Konno K, Komatsuda T, Abe K. Primary leiomyosarcoma of the greater omentum. J Clin Gastroenterol. 1999 Mar. 28(2):167-70. [Medline].
Rao SR, Rao RS, Sampat MB. Hemangiopericytoma of greater omentum. Indian J Gastroenterol. 2000 Jan-Mar. 19(1):33-5. [Medline].
Shiba H, Misawa T, Kobayashi S, Yokota T, Son K, Yanaga K. Hemangiopericytoma of the greater omentum. J Gastrointest Surg. 2007 Apr. 11(4):549-51. [Medline].
Lipper S, Nunnery EW, Jones KL. Pedunculated fibrosarcoma. Unusual presentation of an intraabdominal fibrosarcoma arising from the greater omentum. Am J Surg. 1980 Sep. 140(3):457-61. [Medline].
Beebe MM, Smith MD. Omental lipoblastoma. J Pediatr Surg. 1993 Dec. 28(12):1626-7. [Medline].
Alam K, Maheshwari V, Sabir F, Haq ME, Siddiqui FA, Mefuzuddin S. Glomus tumor of lesser omentum--a case report. Indian J Pathol Microbiol. 2007 Jul. 50(3):543-4. [Medline].
Naik R, Baliga PB, Pai MR, Nayak KS, Shankarnarayanan. Benign teratoma of the lesser omentum--a case report. Indian J Pathol Microbiol. 2003 Jul. 46(3):461-3. [Medline].
Hertzanu Y, Mendelsohn DB, Murray JF. Leiomyoblastoma of the omentum. A case report. S Afr Med J. 1982 Aug 21. 62(9):297-8. [Medline].
Mahon DE, Carp NZ, Goldhahn RT Jr, Schmutzler RC 3rd. Primary leiomyosarcoma of the greater omentum: case report and review of the literature. Am Surg. 1993 Mar. 59(3):160-3. [Medline].
Matsuo S, Susumu S, Tsutsumi R, Azuma T, Obata S, Hayashi T. Glomus tumor of the omentum: a case report. J Surg Oncol. 2007 Dec 1. 96(7):633-6. [Medline].
Ruan CW, Lee CL, Yen CF, Wang CJ, Soong YK. A huge 6.2 kilogram uterine myoma coinciding with omental leiomyosarcoma: case report. Changgeng Yi Xue Za Zhi. 1999 Dec. 22(4):639-42. [Medline].
Rye BA, Christiansen E, Larsen LG. Acute bleeding from leiomyoblastoma of the greater omentum. A case report. Tumori. 1989 Jun 30. 75(3):296-8. [Medline].
Tsutsumi H, Ohwada S, Takeyoshi I, Izumi M, Ogawa T, Fukusato T, et al. Primary omental liposarcoma presenting with torsion: a case report. Hepatogastroenterology. 1999 May-Jun. 46(27):2110-2. [Medline].
Cao L, Hu X, Zhang Y, Sun XT. Omental milky spots in screening gastric cancer stem cells. Neoplasma. 2011. 58(1):20-6. [Medline].
Miyazawa M, Naritaka Y, Miyaki A, Asaka S, Isohata N, Yamaguchi K, et al. A low-grade myofibroblastic sarcoma in the abdominal cavity. Anticancer Res. 2011 Sep. 31(9):2989-94. [Medline].
Hebra A, Brown MF, McGeehin KM. Mesenteric, omental, and retroperitoneal cysts in children: a clinical study of 22 cases. South Med J. 1993 Feb. 86(2):173-6. [Medline].
O'Brien JG, Allen JE, Queen TA. Leiomyoma of the omentum in a child. J Pediatr Surg. 1986 Nov. 21(11):981-2. [Medline].
Lee JT, Kim MJ, Yoo KS, Suh JH, Leong HJ. Primary leiomyosarcoma of the greater omentum: CT findings. J Comput Assist Tomogr. 1991 Jan-Feb. 15(1):92-4. [Medline].
Kadow C, Amery AH. Primary liposarcoma of the omentum: a rare intra-abdominal tumour. Br J Clin Pract. 1989 Dec. 43(12):460-2. [Medline].
Okajima Y, Nishikawa M, Ohi M, Fukumoto Y, Kuroda K, Shimomukai H. Primary liposarcoma of the omentum. Postgrad Med J. 1993 Feb. 69(808):157-8. [Medline].
Wong PP, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer. 1978 Apr. 41(4):1256-60. [Medline].
Patel Shreyaskumar R, Wong Patrick. Efficacy of Imatinib in Unresectable Gastrointestinal Stromal Tumors. US Oncol Rev. 2009. 5(1):61-4. [Full Text].
Okuno S. The Use of Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors (GIST). Contemporary Oncol. March 15, 2011. [Full Text].
"News: Genetic Variations in GI Tumors Determine Which Medications Are Efficacious.". Genetic Engineering & Biotechnology News. Nov 2008.
Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014 Aug 1. 120 (15):2325-33. [Medline].
|Tumor Histology||Number of Cases||% of Total|
|Spindle cell sarcoma||1||1|
|Malignant fibrous histiocytoma||1||1|
|Gastrointestinal stromal tumor||21||16|